Home › Geographic Atrophy › Maryland › Hagerstown
Geographic Atrophy clinical trials in Hagerstown, MD
5 studies for Geographic Atrophy are looking for participants at sites in and around Hagerstown (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RecruitingPhase 2/3
- Cumberland Valley Retina Consultants, Hagerstown
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RecruitingPhase 1/2
- Cumberland Valley Retina Consultants - Hagerstown- Site Number : 8400003, Hagerstown
A Study in Adults With Geographic Atrophy
RecruitingPhase 2
- Cumberland Valley Retina Consultants,P.C., Hagerstown
- Mid Atlantic Retina Specialists, Hagerstown
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- Cumberland Valley Retina Consultants-Ophthalmology, Hagerstown
- Mid Atlantic Retina Specialist, Hagerstown
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- Cumberland Valley Retina Consultants, Hagerstown
Geographic Atrophy trials in other cities
- Reno, NV8 studies
- Dallas, TX8 studies
- Austin, TX7 studies
- Santa Monica, CA7 studies
- Cleveland, OH6 studies
- Naperville, IL6 studies
- The Woodlands, TX6 studies
- Baltimore, MD6 studies
- Houston, TX6 studies
- St. Louis, MO5 studies
- Washington, DC5 studies
- Spokane, WA5 studies
Other studies in Hagerstown
- Macular Degeneration8 studies
- Wet Macular Degeneration4 studies
- Macular Edema4 studies
- Psoriatic Arthritis3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.